Eli Lilly’s Omvoh shows long-term effectiveness against UC, Crohn’s disease
Eli Lilly's Omvoh shows long-term efficacy against ulcerative colitis and Crohn's disease, with high rates of remission ...
BioSpace14h
Lilly and J&J Face Off in Crohn’s Disease With Phase III Readouts at ACG 2024
Eli Lilly and Johnson & Johnson are seeking label expansions for Omvoh and Tremfya, respectively, in Crohn’s disease ...
GlobalData on MSN9h
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
After both receiving FDA approval in UC, J&J and Eli Lilly are racing for their IL-23 inhibitors to get the green light in ...
Eli Lilly's Mirikizumab Shows Long-Term Sustained Efficacy, Safety For Ulcerative Colitis And Crohn's Disease
Eli Lilly announced that mirikizumab achieved long-term remission in Phase 3 IBD studies, showing promise for ulcerative ...
Zacks.com on MSN6h
Can Mounjaro, Zepbound Help Eli Lilly Top Earnings Estimates Again?
Eli Lilly LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for ...
Eli Lilly announces results from two, multi-year mirikizumab studies
Eli Lilly (LLY) announced results from two, multi-year, Phase 3 studies that showed patients treated with mirikizumab sustained stable, ...
Zacks.com on MSN5d
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
Eli Lilly and Company LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus ...
pharmaphorum5d
AbbVie breaks new ground for IL-23 drug Skyrizi in IBD
In UC, Skyrizi faces direct competition from Eli Lilly’s IL-23 inhibitor Omvoh (mirikizumab), approved by the FDA last year, although that isn’t yet approved for Crohn’s disease. The IBD ...